XSHE
000627
Market cap1.09bUSD
Aug 13, Last price
1.58CNY
Name
Hubei Biocause Pharmaceutical Co.
Chart & Performance
P/E
—
P/S
0.16
EPS
—
Div Yield, %
—
Shrs. gr., 5y
0.41%
Rev. gr., 5y
9.93%
Revenues
49.70b
+0.17%
Net income
-652m
L
CFO
9.53b
+26.71%
Dividend
May 30, 20230.11 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. The company also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, it is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. The company exports its products to the United States, the European Union, and internationally. Hubei Biocause Pharmaceutical Co., Ltd. is based in Jingmen, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||